ArticleScientific reports2026
Screening of a potential coxsackievirus B4 vaccine strain through analysis of biological features.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coxsackievirus B4 (CVB4) is a major pathogen involved in hand, foot, and mouth disease as well as aseptic meningitis, and is associated with type 1 diabetes mellitus. Currently, no effective antiviral drugs or vaccines are available for CVB4 infections. Drawing on successful experience with inactivated vaccines for enterovirus 71 and poliovirus, we developed an inactivated CVB4 vaccine based on Vero cells. The highly pathogenic CVB4 virus strain 140/CHN/2019, isolated from Vero cells and classified as genotype D, reflecting the circulating strains in China. Through three cycles of plaque assays and successive passages, the clone strain KM140-G01 could adapt to Vero cells and grew to a titer exceeding 10⁷ CCID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.